3 products found

Microbiotica Limited products

Microbiotica - Microbiome-Based Biomarkers Drug

Microbiotica accesses high quality large-scale clinical datasets in order to identify microbiome-based biomarkers of drug response, drug side-effects or disease progression. The company has accessed the clinical data from academic/clinical collaborations (University of Adelaide, Cambridge University Hospitals/Cancer Research UK) or from pharma partners (Genentech/Roche).

Microbiotica - Discovery Platform Microbiotica Drug

A fundamental challenge to any microbiome program is that human gut bacteria have been viewed as unculturable, and the microbiome of any individual could not be characterised with sufficient depth and precision to form a sound basis for translation. Thus metagenomics routinely can classify only 50 % of gut bacterial sequences, meaning that a very large fraction of gut bacteria are not seen, compromising the association between particular bacteria and biology or patient phenotype.

Microbiotica - Bacterial Therapeutics (LBT)

Microbiotica’s best-in-class live bacterial therapeutics (LBT) are defined consortia of precision-selected naturally occurring, safe bacteria, manufactured and dosed orally in a capsule. These LBT undergo targeted release and will stably engraft in the intestine, producing a long-term therapeutic effect. The products target multiple biological mechanisms in the body (epithelial, immunological, neuronal etc.) providing a more comprehensive shirt from disease to healthy status.